TBPH

Theravance Biopharma, Inc.

NasdaqAdd to watchlist

Healthcare · Biotechnology

$17.02

−$0.04−0.23%

Delayed · 2026-09-10T20:00:00.000Z · marketstack

Aug 11, 2026$17.02

+$0.10+0.59%over 1M

Day range40% of range

$17.00$17.05

Session

Previous close: $17.06
Open: $17.05
Volume: 324.53K
Avg volume: -
Day high: $17.05
Day low: $17.00

Fundamentals

Visualize fundamentals and more

Market cap: 879.37M
P/E ratio: 16.34
EPS (TTM): $1.04
Dividend yield: -
Beta: 0.26
Shares outstanding: 51.67M

Source SEC EDGAR · 9/11/2026

Risk factors, year on year

Item 1AMarch 2026 10-KMarch 2025as filed.

added: 43
dropped: 52
re-drafted: 74

Out of 213 passages in this year’s Item 1A.

The assistant has not been given these passages. It will say so, and say what opens them. This costs you no question.

New this year

● We and/or our collaboration partners and those commercializing products with respect to which we have an economic interest may face competition from companies seeking to market generic versions of any approved products in which we have an interest, such as …

94 more passages, included withBespoke

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Data privacy
Litigation
Tax
Product recalls
Key people
Cybersecurity

And 14 more.

FDA approval
Accordingly, other companies may succeed in obtaining patent protection, conducting clinical trials, receiving FDA or equivalent regulatory approval outside the US or discovering, developing and commercializing medicines more successfully than we do. Other …

7 more themes, included withMeasure

Recent activity

Sep 10Other eventCompany filing8-K

22 more events, included withMeasure

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Companies like Theravance Biopharma, Inc.

Also filed under Biotechnology, ranked by how closely they sit beside TBPH.

MRNAModerna, Inc.
ALNYALNYLAM PHARMACEUTICALS, INC.
REGNREGENERON PHARMACEUTICALS, INC.
VRTXVERTEX PHARMACEUTICALS INC / MA
INSMINSMED Inc
ARGXARGENX SE

Ask about Theravance Biopharma, Inc.

The assistant answers from what TBPH has actually filed: 14 annual reports filed with the SEC, 49 Form 4 filings from the last year and 3 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Pressing one answers it here, from TBPH's filings and figures. One a day without an account; a free account has its own, and no card.

See every investor holding Theravance Biopharma, Inc., and every quarter they moved.

Ten seconds, no card, and nothing to cancel.

What an account lets you do with Theravance Biopharma, Inc.

Separate the decisions from the paperwork
Every Form 4 TBPH insiders have filed, with vesting and automatic tax sales struck out: what's left is the buys and sells somebody actually chose to make.
Every filingMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: who added, who trimmed, who walked away.
Every position they holdMeasure
Interrogate the filing, not the internet
Ask anything about Theravance Biopharma, Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free accountSee what the paid plans add

Free, no card, and it does not expire.